Inici › Mielofibrosi › Massachusetts › Boston
Assaigs clínics de Mielofibrosi a Boston, MA
12 estudis de Mielofibrosi busquen participants en centres de Boston i voltants (en un radi d'uns 30 milles). Obre un estudi per veure qui hi pot participar i com contactar amb l'equip.
Text oficial de l'estudi (anglès)
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
ReclutantFase 1/2
- Massachusetts General Hospital, Boston
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
ReclutantFase 3
- Tufts Medical Center, Boston
A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
ReclutantFase 1
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis
ReclutantFase 1/2
- Massachusetts General Hospital (Data Collection Only), Boston
A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
ReclutantFase 1Voluntaris sans benvinguts
- Brigham and Women's Hospital, Boston
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
ReclutantFase 1
- Massachusetts General Hospital, Boston
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
ReclutantFase 1
- Dana Farber Cancer Institute, Boston
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
ReclutantFase 1
- Dana Farber Cancer Institute, Boston
Momelotinib During and After HCT in Myelofibrosis
ReclutantFase 1
- Massachusetts General Hospital, Boston
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
ReclutantFase 2
- Dana-Farber Cancer Institute, Boston
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
ReclutantFase 2Voluntaris sans benvinguts
- DFCI/BWH Brigham and Women's Hospital, Boston
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
ReclutantFase 3
- Dana Farber Cancer Institute, Boston
Assaigs de Mielofibrosi en altres ciutats
- Houston, TX19 estudis
- New York City, NY18 estudis
- Durham, NC12 estudis
- Columbus, OH11 estudis
- Seattle, WA11 estudis
- Salt Lake City, UT10 estudis
- Miami, FL10 estudis
- Nashville, TN9 estudis
- Cleveland, OH9 estudis
- Tampa, FL9 estudis
- Atlanta, GA9 estudis
- Baldwin Park, CA9 estudis
Altres estudis a Boston
- Càncer de mama111 estudis
- Càncer de pulmó de cèl·lules no petites90 estudis
- Càncer (tots els tipus)86 estudis
- Càncer colorrectal63 estudis
- Càncer metastàtic63 estudis
- Càncer de pulmó62 estudis
- Càncer d'ovari61 estudis
- Càncer de pròstata59 estudis
- Depressió52 estudis
- Càncer d'endometri50 estudis
- Insuficiència cardíaca44 estudis
- Leucèmia mieloide aguda44 estudis
De ClinicalTrials.gov, dades recuperades el 5 d’oct. 2026. Cada estudi estableix els seus propis criteris d'elegibilitat; l'equip de l'estudi decideix qui hi pot participar.